Q2 EPS Estimate for Theravance Biopharma Lifted by Analyst

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Stock analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for Theravance Biopharma in a research report issued on Wednesday, March 4th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of $0.19 for the quarter, up from their previous forecast of ($0.19). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q3 2026 earnings at $0.28 EPS, Q4 2026 earnings at $2.02 EPS and FY2026 earnings at $2.37 EPS.

Other analysts have also recently issued research reports about the stock. B. Riley Financial reissued a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday. BTIG Research cut their price objective on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $13.58 on Friday. The company’s fifty day moving average price is $19.06 and its two-hundred day moving average price is $16.83. The firm has a market capitalization of $688.10 million, a PE ratio of 23.82 and a beta of 0.17. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $21.03.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors have recently modified their holdings of TBPH. Quarry LP bought a new stake in shares of Theravance Biopharma during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.